Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | MANBA | O00462 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.56 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.56 |
| ▸ | IDUA | P35475 | 1/20 | 0.56 |
| ▸ | GUSB | P08236 | 1/20 | 0.56 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14391479 | 1.00 | LMNA (1.00) | LMNAHIF1AMANBATHRBCYP2C19 | |
| SCHEMBL16687559 | 1.00 | LMNA (1.00) | LMNAHIF1AMANBATHRBCYP2C19 | |
| SCHEMBL14296856 | 1.00 | LMNA (1.00) | LMNAHIF1AMANBATHRBCYP2C19 | |
| SCHEMBL12216738 | 1.00 | LMNA (1.00) | LMNAHIF1AMANBATHRBCYP2C19 | |
| SCHEMBL25070350 | 1.00 | LMNA (1.00) | LMNAHIF1AMANBATHRBCYP2C19 | |
| SCHEMBL19638526 | 1.00 | LMNA (1.00) | LMNAHIF1AMANBATHRBCYP2C19 | |
| SCHEMBL23111379 | 1.00 | LMNA (1.00) | LMNAHIF1AMANBATHRBCYP2C19 | |
| SCHEMBL8079451 | 1.00 | LMNA (1.00) | LMNAHIF1AMANBATHRBCYP2C19 | |
| SCHEMBL23532013 | 1.00 | LMNA (1.00) | LMNAHIF1AMANBATHRBCYP2C19 | |
| SCHEMBL17017514 | 1.00 | LMNA (1.00) | LMNAHIF1AMANBATHRBCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120132035-A | Wound surface rapid healing dressing and preparation method thereof | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 2025-06-13 | — | — | CN | claimed |
| CN-119371654-A | Amino lactam and sugar lactone modified lactide high polymer and preparation method thereof | 中鼎凯瑞科技成都有限公司 | 2025-01-28 | — | — | CN | claimed |
| EP-4716736-A1 | POLYMERS, AQUEOUS COMPOSITIONS COMPRISING SUCH POLYMERS, AND USE AS LAUNDRY DETERGENTS | BASF SE (DE) | 2026-04-01 | — | — | EP | disclosed |
| CN-120132035-A | Wound surface rapid healing dressing and preparation method thereof | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 2025-06-13 | — | — | CN | disclosed |
| CN-119371654-A | Amino lactam and sugar lactone modified lactide high polymer and preparation method thereof | 中鼎凯瑞科技成都有限公司 | 2025-01-28 | — | — | CN | disclosed |
| WO-2024240520-A1 | POLYMERS, AQUEOUS COMPOSITIONS COMPRISING SUCH POLYMERS, AND USE AS LAUNDRY DETERGENTS | BASF SE (DE) | 2024-11-28 | — | — | WO | disclosed |
| US-12029790-B2 | Biomimetic nanomaterials and uses thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240057589-A1 | EFFERVESCENT SOLID DOSAGE FORM COMPOSITIONS CONTAINING ENVIRONMENTALLY SAFER ANTI-MICROBIAL COMPONENTS | CHEMLINK LABORATORIES, LLC | 2024-02-22 | — | — | US | disclosed |
| CN-113933430-B | High-sensitivity and high-precision analysis method suitable for detecting organic sulfur compounds in main stream smoke of cigarettes | 中国烟草总公司郑州烟草研究院 | 2023-09-05 | — | — | CN | disclosed |
| WO-2023088777-A1 | COMPOSITIONS COMPRISING POLYMERS, POLYMERS, AND THEIR USE | BASF SE (DE) | 2023-05-25 | — | — | WO | disclosed |
| WO-2022146771-A1 | EFFERVESCENT SOLID DOSAGE FORM COMPOSITIONS CONTAINING ENVIRONMENTALLY SAFER ANTI-MICROBIAL COMPONENTS | CHEMLINK LABORATORIES, LLC (US) | 2022-07-07 | — | — | WO | disclosed |
| CN-1835889-A | Process for producing hydroxylamine | SHOWA DENKO KK (JP) | 2006-09-20 | — | — | CN | disclosed |
| US-20060084817-A1 | Synthesis of aldonolactones, aldarolactones, and aldarodilactones using gas sparging | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-04-20 | — | — | US | disclosed |
| US-20060084800-A1 | Synthesis of aldonolactones, aldarolactones, and aldarodilactones using azeotropic distillation | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-04-20 | — | — | US | disclosed |
| WO-2006005070-A1 | SYNTHESIS OF ALDONOLACTONES, ALDAROLACTONES, AND ALDARODILACTONES USING GAS SPARGING | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006005071-A1 | SYNTHESIS OF ALDONOLACTONES, ALDAROLACTONES, AND ALDARODILACTONES USING AZEOTROPHIC DISTILLATION | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2006-01-12 | — | — | WO | disclosed |
| EP-1018337-B1 | Formulations containing chlorhexidine and novel chlorhexidine salts | DEGUSSA (DE) | 2003-02-05 | — | — | EP | disclosed |
| US-6500466-B2 | POWDERED MIXTURE; STORAGE STABILITY | DEGUSSA AG (DE) | 2002-12-31 | — | — | US | disclosed |
| US-20020018814-A1 | CHLORHEXIDINE FORMULATIONS, NEW CHLORHEXIDINE SALTS, SOLUTIONS CONTAINING THESE AND THEIR USE | EVONIK DEGUSSA GMBH (DE) | 2002-02-14 | — | — | US | disclosed |
| EP-1018337-A2 | Formulations containing chlorhexidine, novel chlorhexidine salts,solutions containing the aforesaid chlorhexidine salts and their use | Degussa-Hüls Aktiengesellschaft (DE) | 2000-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020018814-A1 | CHLORHEXIDINE FORMULATIONS, NEW CHLORHEXIDINE SALTS, SOLUTIONS CONTAINING THESE AND THEIR USE | GMDS, G6PD, GALC | LMNA 2593/4885HIF1A 1481/4885MANBA 98/4885 |
| US-20060084817-A1 | Synthesis of aldonolactones, aldarolactones, and aldarodilactones using gas sparging | ALDOA, AKR1C2, ADH1C | LMNA 412/4885HIF1A 2244/4885MANBA 457/4885 |
| US-12029790-B2 | Biomimetic nanomaterials and uses thereof | MTREX, HAVCR2, TSG101 | LMNA 139/4885HIF1A 222/4885MANBA 1877/4885 |
| US-20060084800-A1 | Synthesis of aldonolactones, aldarolactones, and aldarodilactones using azeotropic distillation | ADH1C, ALDOA, AKR1C2 | LMNA 638/4885HIF1A 3788/4885MANBA 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.